---
document_datetime: 2025-12-02 05:36:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/verquvo.html
document_name: verquvo.html
version: success
processing_time: 0.1094443
conversion_datetime: 2025-12-28 01:38:01.863341
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Verquvo

[RSS](/en/individual-human-medicine.xml/67461)

##### Authorised

This medicine is authorised for use in the European Union

vericiguat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Verquvo](#news-on)
- [More information on Verquvo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Verquvo is a medicine used to treat adults with long-term heart failure with reduced ejection fraction who recently received treatment given intravenously (into a vein) because their symptoms had worsened. Heart failure with reduced ejection fraction is when the heart does not pump blood as well as it should, especially when the amount of blood being pumped out of the heart is less than the body needs. Some common symptoms of heart failure are shortness of breath, tiredness, or swelling caused by a build-up of fluid.

Verquvo contains the active substance vericiguat.

Expand section

Collapse section

## How is Verquvo used?

Verquvo can only be obtained with a prescription. It is given in combination with other treatments for heart failure and is available as tablets. The recommended starting dose is 5 mg once a day. The doctor may lower the starting dose to 2.5 mg if the patient has symptomatic hypotension (low blood pressure with symptoms such as light-headedness).

The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once a day, if tolerated. The dose should be lowered or treatment should be stopped if the patient does not tolerate the medicine well.

For more information about using Verquvo, see the package leaflet or contact your doctor or pharmacist.

## How does Verquvo work?

The active substance in Verquvo, vericiguat, stimulates an enzyme (a type of protein) called soluble guanylate cyclase (sGC) in the blood vessels, which causes them to relax and widen, making it easier for the heart to pump blood out.

## What benefits of Verquvo have been shown in studies?

Verquvo has been shown to be effective in treating heart failure in one main study involving over 5,000 patients with long-term heart failure and reduced ejection fraction who had been recently

treated for an increase in their symptoms. In the study, which lasted around one year, patients were given either Verquvo or placebo (a dummy treatment) in combination with other medicines for heart failure.

In the group treated with Verquvo, 35.5% of patients (897 out of 2,526) either died as a result of heart and circulation problems or were admitted to hospital with heart failure, compared to 38.5% (972 out of 2,524) of patients given placebo.

## What are the risks associated with Verquvo?

For the full list of side effects and restrictions of Verquvo, see the package leaflet.

The most common side effect with Verquvo (which may affect more than 1 in 10 people) is hypotension (low blood pressure).

Verquvo must not be used together with other sGC stimulators, such as riociguat.

## Why is Verquvo authorised in the EU?

The main study found that Verquvo reduced deaths from heart and circulation problems or hospital admissions for heart failure. Although the effect compared to placebo was modest, it was considered significant considering that the patients included in the study were at high risk of hospitalisation or death. The safety of Verquvo was considered acceptable and the medicine well-tolerated. The European Medicines Agency therefore decided that Verquvo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Verquvo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Verquvo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Verquvo are continuously monitored. Suspected side effects reported with Verquvo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Verquvo

Verquvo received a marketing authorisation valid throughout the EU on 16 July 2021.

Verquvo : EPAR - Medicine overview

Reference Number: EMA/425562/2021

English (EN) (128.8 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 10/11/2025

[View](/en/documents/overview/verquvo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-39)

български (BG) (151.34 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/bg/documents/overview/verquvo-epar-medicine-overview_bg.pdf)

español (ES) (126.56 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/es/documents/overview/verquvo-epar-medicine-overview_es.pdf)

čeština (CS) (149.69 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/cs/documents/overview/verquvo-epar-medicine-overview_cs.pdf)

dansk (DA) (126.11 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/da/documents/overview/verquvo-epar-medicine-overview_da.pdf)

Deutsch (DE) (129.25 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/de/documents/overview/verquvo-epar-medicine-overview_de.pdf)

eesti keel (ET) (125.26 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/et/documents/overview/verquvo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (150.21 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/el/documents/overview/verquvo-epar-medicine-overview_el.pdf)

français (FR) (128.77 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/fr/documents/overview/verquvo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (147.17 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/hr/documents/overview/verquvo-epar-medicine-overview_hr.pdf)

italiano (IT) (124.86 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/it/documents/overview/verquvo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.18 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/lv/documents/overview/verquvo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (149.75 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/lt/documents/overview/verquvo-epar-medicine-overview_lt.pdf)

magyar (HU) (147.81 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/hu/documents/overview/verquvo-epar-medicine-overview_hu.pdf)

Malti (MT) (151.67 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/mt/documents/overview/verquvo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (125.86 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/nl/documents/overview/verquvo-epar-medicine-overview_nl.pdf)

polski (PL) (152.49 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/pl/documents/overview/verquvo-epar-medicine-overview_pl.pdf)

português (PT) (127.1 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/pt/documents/overview/verquvo-epar-medicine-overview_pt.pdf)

română (RO) (148.27 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/ro/documents/overview/verquvo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (149.25 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sk/documents/overview/verquvo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (146.52 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sl/documents/overview/verquvo-epar-medicine-overview_sl.pdf)

Suomi (FI) (124.96 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/fi/documents/overview/verquvo-epar-medicine-overview_fi.pdf)

svenska (SV) (125.5 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sv/documents/overview/verquvo-epar-medicine-overview_sv.pdf)

Verquvo : EPAR - Risk-management-plan summary

English (EN) (74.09 KB - PDF)

**First published:** 27/07/2021

[View](/en/documents/rmp-summary/verquvo-epar-risk-management-plan-summary_en.pdf)

## Product information

Verquvo : EPAR - Product information

English (EN) (783.7 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 10/11/2025

[View](/en/documents/product-information/verquvo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-962)

български (BG) (1.27 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/bg/documents/product-information/verquvo-epar-product-information_bg.pdf)

español (ES) (1.37 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/es/documents/product-information/verquvo-epar-product-information_es.pdf)

čeština (CS) (1.37 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/cs/documents/product-information/verquvo-epar-product-information_cs.pdf)

dansk (DA) (1.3 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/da/documents/product-information/verquvo-epar-product-information_da.pdf)

Deutsch (DE) (1.49 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/de/documents/product-information/verquvo-epar-product-information_de.pdf)

eesti keel (ET) (1.21 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/et/documents/product-information/verquvo-epar-product-information_et.pdf)

ελληνικά (EL) (1.22 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/el/documents/product-information/verquvo-epar-product-information_el.pdf)

français (FR) (1.72 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/fr/documents/product-information/verquvo-epar-product-information_fr.pdf)

hrvatski (HR) (1.45 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/hr/documents/product-information/verquvo-epar-product-information_hr.pdf)

íslenska (IS) (1.34 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/is/documents/product-information/verquvo-epar-product-information_is.pdf)

italiano (IT) (1.45 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/it/documents/product-information/verquvo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.42 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/lv/documents/product-information/verquvo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.59 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/lt/documents/product-information/verquvo-epar-product-information_lt.pdf)

magyar (HU) (1.36 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/hu/documents/product-information/verquvo-epar-product-information_hu.pdf)

Malti (MT) (1.46 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/mt/documents/product-information/verquvo-epar-product-information_mt.pdf)

Nederlands (NL) (1.45 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/nl/documents/product-information/verquvo-epar-product-information_nl.pdf)

norsk (NO) (1.27 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/no/documents/product-information/verquvo-epar-product-information_no.pdf)

polski (PL) (1.51 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/pl/documents/product-information/verquvo-epar-product-information_pl.pdf)

português (PT) (1.11 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/pt/documents/product-information/verquvo-epar-product-information_pt.pdf)

română (RO) (1.22 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/ro/documents/product-information/verquvo-epar-product-information_ro.pdf)

slovenčina (SK) (1.35 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sk/documents/product-information/verquvo-epar-product-information_sk.pdf)

slovenščina (SL) (1.29 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sl/documents/product-information/verquvo-epar-product-information_sl.pdf)

Suomi (FI) (1.26 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/fi/documents/product-information/verquvo-epar-product-information_fi.pdf)

svenska (SV) (1.29 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

10/11/2025

[View](/sv/documents/product-information/verquvo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000257213 24/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Verquvo : EPAR - All authorised presentations

English (EN) (99.45 KB - PDF)

**First published:** 27/07/2021

[View](/en/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-704)

български (BG) (105.48 KB - PDF)

**First published:**

27/07/2021

[View](/bg/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.09 KB - PDF)

**First published:**

27/07/2021

[View](/es/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.17 KB - PDF)

**First published:**

27/07/2021

[View](/cs/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.55 KB - PDF)

**First published:**

27/07/2021

[View](/da/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (169.09 KB - PDF)

**First published:**

27/07/2021

[View](/de/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (99.28 KB - PDF)

**First published:**

27/07/2021

[View](/et/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.38 KB - PDF)

**First published:**

27/07/2021

[View](/el/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_el.pdf)

français (FR) (165.04 KB - PDF)

**First published:**

27/07/2021

[View](/fr/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (102.89 KB - PDF)

**First published:**

27/07/2021

[View](/hr/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.56 KB - PDF)

**First published:**

27/07/2021

[View](/is/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (165.84 KB - PDF)

**First published:**

27/07/2021

[View](/it/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (102.87 KB - PDF)

**First published:**

27/07/2021

[View](/lv/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (174.42 KB - PDF)

**First published:**

27/07/2021

[View](/lt/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (181.84 KB - PDF)

**First published:**

27/07/2021

[View](/hu/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (171.19 KB - PDF)

**First published:**

27/07/2021

[View](/mt/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (231.9 KB - PDF)

**First published:**

27/07/2021

[View](/nl/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.92 KB - PDF)

**First published:**

27/07/2021

[View](/no/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_no.pdf)

polski (PL) (170.04 KB - PDF)

**First published:**

27/07/2021

[View](/pl/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_pl.pdf)

português (PT) (102.98 KB - PDF)

**First published:**

27/07/2021

[View](/pt/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_pt.pdf)

română (RO) (173.53 KB - PDF)

**First published:**

27/07/2021

[View](/ro/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.78 KB - PDF)

**First published:**

27/07/2021

[View](/sk/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (169.07 KB - PDF)

**First published:**

27/07/2021

[View](/sl/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.12 KB - PDF)

**First published:**

27/07/2021

[View](/fi/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (230.08 KB - PDF)

**First published:**

27/07/2021

[View](/sv/documents/all-authorised-presentations/verquvo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Verquvo Active substance vericiguat International non-proprietary name (INN) or common name vericiguat Therapeutic area (MeSH) Heart Failure Anatomical therapeutic chemical (ATC) code C01

### Pharmacotherapeutic group

Cardiac therapy

### Therapeutic indication

Treatment of symptomatic chronic heart failure

## Authorisation details

EMA product number EMEA/H/C/005319

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bayer AG

51368 Leverkusen Germany

Opinion adopted 20/05/2021 Marketing authorisation issued 16/07/2021 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Verquvo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (130.83 KB - PDF)

**First published:** 10/11/2025

[View](/en/documents/procedural-steps-after/verquvo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Verquvo-VR-0000257213 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMADOC-1700519818-1988760

English (EN) (839.7 KB - PDF)

**First published:** 10/11/2025

[View](/en/documents/variation-report/verquvo-vr-0000257213-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Verquvo : EPAR - Public assessment report

Adopted

Reference Number: EMA/394228/2021

English (EN) (4.71 MB - PDF)

**First published:** 27/07/2021

[View](/en/documents/assessment-report/verquvo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Verquvo

Adopted

Reference Number: EMA/CHMP/259029/2021

English (EN) (135.15 KB - PDF)

**First published:** 21/05/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-verquvo_en.pdf)

#### News on Verquvo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

#### More information on Verquvo

- [EMEA-001636-PIP01-14-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001636-pip01-14-m03)
- [Real World Outcomes of Patients Treated with Vericiguat in German Routine Care (ROVER) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000221)

**This page was last updated on** 10/11/2025

## Share this page

[Back to top](#main-content)